Matsui Hisanori, Asami Taiji
Extra Value Generation and General Medicine Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Neuroendocrinology. 2014;99(1):49-60. doi: 10.1159/000357809. Epub 2014 Mar 8.
The hypothalamic peptide kisspeptin (metastin), the endogenous ligand of the G protein-coupled receptor KISS1R, plays a critical role in controlling GnRH release from hypothalamic GnRH neurons and thereby regulates hypothalamic-pituitary-gonadal functions. Although the therapeutic potential of kisspeptin is attractive, its susceptibility to proteolytic degradation limits its utility. To overcome this, KISS1R agonists or antagonists as peptide analogs or small molecules have been investigated. Kisspeptin analogs have been most extensively studied by reducing the length of the peptide from the original 54 amino acids to 10 amino acids or less and by substituting key amino acid residues. Also, 2 investigational kisspeptin agonist analogs have been evaluated in clinical studies in men; in agreement with animal studies, abrupt elevations in gonadotropin and testosterone levels were observed as an acute effect, followed by rapid reductions in these hormones as a chronic effect. Some studies of small-molecule KISS1R antagonists have also been published. In this review, we present a brief overview on kisspeptin/KISS1R physiology in reproductive functions and summarize the available knowledge of both agonists and antagonists. We also focus on the kisspeptin agonist analogs by summarizing key pharmacological findings from both clinical and preclinical studies, and discuss their potential therapeutic utility.
下丘脑肽亲吻素(又名 metastin)是 G 蛋白偶联受体 KISS1R 的内源性配体,在控制下丘脑促性腺激素释放激素(GnRH)神经元释放 GnRH 方面发挥关键作用,从而调节下丘脑 - 垂体 - 性腺功能。尽管亲吻素的治疗潜力颇具吸引力,但其易受蛋白水解降解的特性限制了其应用。为克服这一问题,人们对作为肽类似物或小分子的 KISS1R 激动剂或拮抗剂展开了研究。亲吻素类似物的研究最为广泛,方法是将肽的长度从最初的 54 个氨基酸缩短至 10 个氨基酸或更少,并替换关键氨基酸残基。此外,已有 2 种研究性亲吻素激动剂类似物在男性临床研究中得到评估;与动物研究结果一致,观察到促性腺激素和睾酮水平的突然升高是一种急性效应,随后这些激素迅速降低则是一种慢性效应。关于小分子 KISS1R 拮抗剂的一些研究也已发表。在本综述中,我们简要概述亲吻素/KISS1R 在生殖功能中的生理学,并总结激动剂和拮抗剂的现有知识。我们还通过总结临床和临床前研究的关键药理学发现,重点关注亲吻素激动剂类似物,并讨论它们潜在的治疗用途。